Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cibus (CBUS)
NASDAQ:CBUS
Holding CBUS?
Track your performance easily
CBUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.17 - $23.18
Previous CloseN/A
Volume64.89K
Average Volume (3M)197.44K
Market Cap
$73.03M
Enterprise Value$288.77M
Total Cash (Recent Filing)$5.03M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Mar 20, 2025EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.48
Shares Outstanding26,455,582
10 Day Avg. Volume162,478
30 Day Avg. Volume197,441
Standard Deviation0.39
R-Squared0.06
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)17.59
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market Cap3.95
Enterprise Value/Revenue69.53
Enterprise Value/Gross Profit158.93
Enterprise Value/Ebitda-0.58
Forecast
1Y Price Target
$16.33Price Target Upside558.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Cibus News
PremiumCompany Announcements
Cibus Enhances Board with Appointment of August Moretti
PremiumCompany Announcements
Cibus Reports Strategic Shift and Financial Update
Bulls Say, Bears Say
Bulls Say
Commercialization And Revenue GenerationThe most significant opportunities for trait royalties and revenue generation remain HT1/HT3 in rice and pod shatter reduction in canola, which are developed and targeted for commercialization.
Financial PerformanceCibus reported Q3 revenues of $1.7M, which beat consensus by approximately 143%, driven by collaboration agreements for Soybean contract research.
Technological AdvantageThe 'transformative' nature of Cibus' trait machine gene editing process offers a significant competitive advantage, with higher conversion ratios compared to other techniques like Crispr.
Bears Say
Financial PerformanceCibus reported a net loss of approximately $202 million, primarily due to a significant goodwill impairment charge during the quarter.
Operational GoalsCibus did not meet its stated goal of achieving an operational soybean platform at the cellular level by the end of 2024.
Risks And UncertaintyRisks include dilution risk, execution risk, regulatory risk, demand risk, technology risk, competition risk, and uncertainty related to macroeconomic conditions and geopolitical environment.
---
Ownership Overview
32.49% Insiders
12.00% Mutual Funds
5.28% Other Institutional Investors
44.47% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CBUS FAQ
What was Cibus’s price range in the past 12 months?
Cibus lowest stock price was $2.17 and its highest was $23.18 in the past 12 months.
What is Cibus’s market cap?
Cibus’s market cap is $73.03M.
When is Cibus’s upcoming earnings report date?
Cibus’s upcoming earnings report date is Mar 20, 2025 which is in 60 days.
How were Cibus’s earnings last quarter?
Cibus released its earnings results on Nov 07, 2024. The company reported -$7.63 earnings per share for the quarter, missing the consensus estimate of -$0.873 by -$6.757.
Is Cibus overvalued?
According to Wall Street analysts Cibus’s price is currently Undervalued.
Does Cibus pay dividends?
Cibus does not currently pay dividends.
What is Cibus’s EPS estimate?
Cibus’s EPS estimate is -0.74.
How many shares outstanding does Cibus have?
Cibus has 26,455,582 shares outstanding.
What happened to Cibus’s price movement after its last earnings report?
Cibus reported an EPS of -$7.63 in its last earnings report, missing expectations of -$0.873. Following the earnings report the stock price went up 20%.
Which hedge fund is a major shareholder of Cibus?
Among the largest hedge funds holding Cibus’s share is Swan Global Investments, Llc. It holds Cibus’s shares valued at 115K.
---
Cibus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.33 (558.47% Upside)
$16.33 (558.47% Upside)
Blogger Sentiment
Bullish
CBUS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 35.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $24.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.80%
12-Months-Change
Fundamentals
Return on Equity
-155.86%
Trailing 12-Months
Asset Growth
-53.80%
Trailing 12-Months
Company Description
Cibus
Calyxt, Inc. operates as a healthy food ingredient company. It engages in the development of crops by leveraging processes that occur in nature, combining its gene-editing technology and technical expertise with its commercial strategy to bring healthier ingredients to the market. The company was founded by Daniel F. Voytas and André Choulika on January 8, 2010 and is headquartered in Roseville, MN.
---
CBUS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call revealed significant progress in Cibus's transformation to a commercial gene editing company, with successful trait developments and strategic collaborations. However, financial challenges persist with increased net losses, and there are ongoing regulatory and commercialization hurdles.Read More>---
CBUS Stock 12 Month Forecast
Average Price Target
$16.33
▲(558.47% Upside)
Technical Analysis
Chromadex
―
Kali
―
Alnylam Pharma
―
Crispr Therapeutics AG
―
Ionis Pharmaceuticals
―
Editas Medicine
―
Best Analysts Covering CBUS
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-73.40%
reiterated a buy rating 2 months ago
Copying Amit Dayal's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -73.40% per trade.
---